rnase2 sirna (Sangon Biotech)
Structured Review

Rnase2 Sirna, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rnase2+sirna/rnase2+sirna/10__31083_slash_fbl38957-107-6-15
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Multi-omics Analysis Reveals Molecular Subtype of Mitochondrial Oxidative Stress and Prognostic Model Development in Sepsis"
Article Title: Multi-omics Analysis Reveals Molecular Subtype of Mitochondrial Oxidative Stress and Prognostic Model Development in Sepsis
Journal: Frontiers in Bioscience-Landmark
doi: 10.31083/fbl38957
Figure Legend Snippet: Fig. 9. RNASE2 inhibition attenuates mitochondrial oxidative stress of sepsis. (A,B) Western blots of RNASE2 in RAW264.7 macrophages following treatment with LPS (n = 3). (C) CCK-8 assay of RAW264.7 macrophages (n = 3). (D) Verification of interference
Techniques Used: Inhibition, Western Blot, CCK-8 Assay
Related Articles
Sequencing:Article Title: Multi-omics Analysis Reveals Molecular Subtype of Mitochondrial Oxidative Stress and Prognostic Model Development in Sepsis Article Snippet: Subsequently, the siRNA-transfected cells were stimulated with 500 ng/mL lipopolysaccharide (LPS, Cat# L2630, SigmaAldrich, St. Louis, USA) for an additional 12 hours. .. The target sequence was as follow: Generated:Article Title: Multi-omics Analysis Reveals Molecular Subtype of Mitochondrial Oxidative Stress and Prognostic Model Development in Sepsis Article Snippet: Subsequently, the siRNA-transfected cells were stimulated with 500 ng/mL lipopolysaccharide (LPS, Cat# L2630, SigmaAldrich, St. Louis, USA) for an additional 12 hours. .. The target sequence was as follow: |
![Gene profiling in whole blood samples from patients with malignant nodules and benign nodules, and from nodule-free patients. (A) DEGs between malignant nodule blood samples and benign nodule blood samples [fdr <0.05 and log(fold-change) >0.05]. (B) DEGs between malignant nodule blood samples and benign nodule + no nodule blood samples [fdr <0.05 and log(fold-change) >0.05]. (C) The overlapped DEGs from malignant/benign nodules and malignant/(benign + no nodules) were obtained using VENNY. DEG, differentially expressed gene; fdr, false discovery rate; S100, S100 calcium binding protein P; <t>RNASE2,</t> ribonuclease A family member 2; COX7C, cytochrome c oxidase subunit 7C; C19orf59, mast cell expressed membrane protein 1](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_7297/pmc11737297/pmc11737297__ol-29-03-14878-g00.jpg)